Support Centre
21 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Immunosuppression for progressive membranous nephropathy
DOI 10.1186/ISRCTN99959692
ClinicalTrials.gov identifier
EudraCT number
Public title Immunosuppression for progressive membranous nephropathy
Scientific title
Acronym N/A
Serial number at source G9721265
Study hypothesis To test whether immunosuppression alters the natural history of progressive membranous glomerulonephritis and to compare two types of immunosuppressive treatment: cyclosporin and prednisolone/chlorambucil
Lay summary Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Multi-centre randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Progressive membranous glomerulonephritis
Participants - inclusion criteria 1. Idiopathic membranous nephropathy with a 20% decline in glomerular filtration rate
2. Patients aged between 18 and 75
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 15/01/1999
Anticipated end date 31/03/2009
Status of trial Completed
Patient information material
Target number of participants 120 (40 in each group), interim follow-up at 2 years, final follow-up at 5 years. Added 23/09/09: Closed to recruitment, 108 recruited, in follow-up.
Interventions Randomisation will be between three groups:
1. One receiving supportive treatment only
2. One receiving 12 months treatment with cyclosporin
3. One receiving six months treatment with a combination of prednisolone and chlorambucil
Primary outcome measure(s) Glomerular filtration rate with a further decline of 20% being an end-point
Secondary outcome measure(s) Proteinurea and adverse effects
Sources of funding Medical Research Council (MRC) (UK)
Trial website
Publications 1. 2013 results in http://www.ncbi.nlm.nih.gov/pubmed/23312808
Contact name Professor  Peter  Mathieson
  Address Academic Renal Unit
University of Bristol
Southmead Hospital
  City/town Bristol
  Zip/Postcode BS10 5NB
  Country United Kingdom
Sponsor University of Bristol (UK)
  Address Senate House
Tyndall Avenue
  City/town Bristol
  Zip/Postcode BS8 1TH
  Country United Kingdom
  Tel +44 (0)117 928 9000
  Sponsor website: http://www.bris.ac.uk/
Date applied 25/10/2000
Last edited 01/02/2013
Date ISRCTN assigned 25/10/2000
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.